The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIX.i

Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

Publications

Alvarez Cardona A, Hernández Nieto L, Pérez Gómez M, Pedroza Meléndez A, Huerta López JG

[Etoposide desensitization. A case report].

Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) 2010 Jan-Feb;57;33-6 — 2010 Jan-Feb — 33-6

Siderov J, Prasad P, De Boer R, Desai J

Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide.

British journal of cancer 2002 Jan 07;86;12-3 — 2002 Jan 07 — 12-3

de Souza P, Friedlander M, Wilde C, Kirsten F, Ryan M

Hypersensitivity reactions to etoposide. A report of three cases and review of the literature.

American journal of clinical oncology 1994 Oct;17;387-9 — 1994 Oct — 387-9

O'Dwyer PJ, Weiss RB

Hypersensitivity reactions induced by etoposide.

Cancer treatment reports 1984 Jul-Aug;68;959-61 — 1984 Jul-Aug — 959-61

Kasperek C, Black CD

Two cases of suspected immunologic-based hypersensitivity reactions to etoposide therapy.

The Annals of pharmacotherapy 1992 Oct;26;1227-30 — 1992 Oct — 1227-30